Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

This study has been terminated.
(Discontinuation due to the high response rate at the 1st stage and slow accrual.)
Sponsor:
Collaborators:
Genentech, Inc.
Biogen Idec
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00588822
First received: December 20, 2007
Last updated: April 3, 2014
Last verified: April 2014

December 20, 2007
April 3, 2014
January 2005
January 2009   (final data collection date for primary outcome measure)
Percentage of Subjects With at Least 10 Points Improvement in the Neuropathy Impairment Score (NIS) for Either Side of the Body at 6 Months [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]

The Neuropathy Impairment Score [previously called the Neurologic Disability Score (NDS)] is derived from a neurologic examination obtained in a standard way by a specially trained neurologist. Decisions are based on the neurologist's judgment of what is normal considering site, age, sex, weight, height, and physical fitness. The instrument has 35 items, each ranked for left and right sides of the body; weakness is scored 0=normal, 1=25% disability, 2=50% disability, 3=75% disability and 4=100% disability. NIS total score was calculated as the sum of the 35 items, ranging from 0 to 140, with higher score indicating greater disability or impairment.

The neurologist measured the NIS score on both sides of the body, but recorded worst score and reported as 1 for each individual subject (i.e., each subject had only 1 reported score.)

Improvement was defined as at least 10 points improvement in NIS total score, that is, reduction in the number of points on the scale.

The proportion of patients having sustained a successful response, as measured by the neuropathy impairment score (NIS) at 6 months [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00588822 on ClinicalTrials.gov Archive Site
  • Percentage of Subjects Whose Disease Has Stabilized or Responded, for Either Side of the Body, as Measured by NIS at 6 Months [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]

    The Neuropathy Impairment Score (previously called the Neurologic Disability Score [NDS]) is derived from a neurologic examination obtained in a standard way by a specially trained neurologist. Decisions are based on the neurologist's judgment of what is normal considering site, age, sex, weight, height, and physical fitness. The instrument has 35 items, each ranked for left and right sides of the body; weakness is scored 0=normal, 1=25% disability, 2=50% disability, 3=75% disability and 4=100% disability. NIS total score was calculated as the sum of the 35 items, ranging from 0 to 140, with higher score indicating greater disability or impairment.

    The NIS score was measured on both sides of the body, the worst score recorded reported as 1 for each individual subject. Stability was defined as change of less than 10 points in the NIS total score. Improvement was defined as at least 10 points improvement in NIS total score, that is, reduction in the number of points on the scale.

  • Percentage of Subjects With at Least 1 Grade Improvement in the Modified Rankin Score at 6 Months [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]
    The Modified Rankin Scale was used to determine functional disability as follows: 0 = asymptomatic; 1 = symptoms not interfering with manual activities/walking normally; 2 = minor difficulties in manual activities/walking independently without support; 3 = unable to perform some manual activities/walking independently with support; 4 = unable to eat, dress or wash independently/needing assistance to walk; 5 = no useful tasks performed with upper limbs/confined to wheelchair. Therefore, scores could range from 0 to 5, with higher values indicating greater disability.
  • Percentage of Patients Having Improvement in the Hand Grip Strength Ergometry Value for Either Hand at 6 Months [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]
    Grip strength was measured by a dynamometer in both hands at baseline and every three months until the final study visit. Response criteria was defined as achieving improvement in hand grip strength dynamometry values (>10% better relative to baseline at the 6 month visit on either side).
  • Percentage of Subjects Having One or More Stable Hand Grip Strength Ergometry Values for Either Hand at 6 Months [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]
    Grip strength was measured by a dynamometer in both hands at baseline and every three months until the final study visit. Response criteria was defined as achieving stable hand grip strength dynamometry values (no more than 10% better or worse relative to baseline at the 6 month visit on either side).
  • Percentage of Subjects With > 50% Reduction of Monoclonal Protein Titer at 6 Months [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]
    Monoclonal immunoglobulins measured included Immunoglobulin G (IgG), Immunoglobulin A (IgA), and Immunoglobulin M (IgM).
  • The proportion of patients whose disease has stabilized, as measured by NIS at 6 months [ Designated as safety issue: No ]
  • The proportion of patients with > 1 mV increase in the summated CMAP amplitude at 6 months [ Designated as safety issue: No ]
  • The proportion of patients with > 1 grade improvement in the modified Rankin Score at 6 months [ Designated as safety issue: No ]
  • The proportion of patients having improvement in the hand grip strength ergometry value for either hand at 6 months [ Designated as safety issue: No ]
  • The proportion of patients having one or more stable hand grip strength ergometry values for either hand at 6 months [ Designated as safety issue: No ]
  • The proportion of patients with > 50% reduction of monoclonal protein titer at 6 months [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
A Phase II Trial of Rituximab for Peripheral Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS)

This study was done to find out if the investigational medication, rituximab, could help relieve the symptoms of peripheral neuropathy (such as numbness [abnormal protein in the blood] and weakness of the lower and upper extremities) in people who have monoclonal gammopathy of undetermined significance and people with a symptomatic or smoldering Waldestrom macroglobulinemia.

Rituximab is an antibody which attacks a particular type of white blood cell (B Cell). By targeting the B-cells which make the abnormal protein which is involved in causing the nerve trouble, it is hoped that damage to nerve fibers will be stopped and improvement will be allowed to proceed.

This was a Phase II single arm trial evaluating the use of Rituximab administered at standard dose and schedule as an initial cycle of therapy, followed by a re-evaluation at 6 months.

If progression in neuropathy (as indicated by an increase in the Neuropathy Impairment Score (NIS) of greater than or equal to 10 or a modified Rankin Score increase of > 1 grade) the patient was off study. In addition, if the subject elected to pursue other active treatment including but not limited to plasmapheresis, high-dose intravenous immuneglobulin (IVIG), chemotherapeutic agents, or high dose corticosteroids, or if conditions in the exclusion criteria develop subsequent to enrollment, the subject was off study.

If the neuropathy is stable or responding (NIS of < 10 or a modified Rankin Score increase of < 1 grade) the patient would have received Cycle 2 of rituximab followed by a reevaluation at 12 months.

The study had a Simon Optimal two-stage Phase II design (α 5%, β 10%, π0 5%, π1 20%). The minimum clinically important response rate was 20%. The first stage was to include 21 patients and the second stage a total of 41 patients. The treatment would be rejected if there were fewer than 2 responders at the first stage or fewer than 5 responders at the second stage. The treatment would be accepted for further study if there were at least 5 responders out of 41 patients.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Precancerous Condition
Biological: Rituximab
Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
Other Name: Rituxan
Experimental: Rituximab

Subjects will receive rituximab administered at the standard dose and schedule as an initial cycle of therapy, followed by a re-evaluation at 6 months. If the neuropathy is stable or responding at 6 months, the subject will receive Cycle 2 of rituximab, followed by a re-evaluation at 12 months.

Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).

Intervention: Biological: Rituximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
21
February 2011
January 2009   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of monoclonal gammopathy of undetermined significance (MGUS), as evidenced by 1 of the following criteria:

    • Documented monoclonal protein in the serum (< 3 g/dL) or urine
    • Monoclonal serum free light chain, with at least 50% of patients having an immunoglobulin M (IgM) paraprotein (the balance being immunoglobulin G (IgG) or immunoglobulin A (IgA) subtypes)
  • Neuropathy Impairment Score (NIS) ≥ 25
  • Stable or progressive neuropathy (i.e., not currently improving), as judged by NIS values that have not fallen ≥ 10 (between enrollment and the last documented value), at least 1 month but not greater than 3 months prior to enrollment
  • No evidence of amyloidosis or overt lymphoma, overt myeloma, or Waldenström macroglobulinemia with end organ damage
  • No evidence of multiple myeloma, Amyloid Light-chain (AL)-amyloidosis
  • No evidence of Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, diabetes mellitus, alcohol induced neuropathy, untreated hypothyroidism, vitamin B12 deficiency, Sjögren syndrome, and other causes of neuropathy

PATIENT CHARACTERISTICS:

Inclusion Criteria:

  • Not pregnant
  • Negative serum pregnancy test
  • Fertile patients must use an acceptable method of birth control during treatment and for 6 months after completion of treatment

    • One of the following birth control measures must be used: birth control pills, intrauterine device, contraceptive injections (Depo-Provera), barrier methods such diaphragm, condom or contraceptive sponge with spermicide
  • Adequate bone marrow function as indicated by sufficient precursors of all three cell lines and cellularity of at least 20% on bone marrow biopsy within 6 months
  • Platelets > 100,000/mm^3
  • Absolute neutrophil count (ANC) > 1,000/mm^3
  • Hemoglobin > 7 g/dL
  • Serum creatinine < 3.0 mg/dL
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 times upper limit of normal
  • No history of psychiatric disorder requiring hospitalization, psychiatric consultation, or psychotropic medications within the last year

    • Patients with controlled depression are eligible, as defined by the following:

      • Stable for at least 6 months
      • No increase in psychotropic medications

Exclusion criteria:

  • History of HIV infection or seropositivity
  • History or serological profile suggesting prior hepatitis B virus (HBV) infection (i.e., HbsAg or anti-HBs with anti-HBc)

    • Prior HBV vaccination with isolated anti-HBs antibodies is not an exclusion criterion
  • HBV infection or non-vaccination-related HBV seropositivity
  • Active infection
  • New York Heart Association class III or IV heart disease
  • History or baseline ECG tracing demonstrating severe recurrent or severe recent (within 3 months) cardiac dysrhythmia (e.g., ventricular tachycardia, torsades de pointes ("Twisting of the Points," a rapid polymorphic Ventricular Tachycardia), or other serious ventricular dysrhythmias) requiring implanted defibrillator treatment
  • Confirmed diagnosis of systemic lupus erythematosus (SLE)

    • An isolated low titer positive antinuclear antibody test without clinical evidence of SLE is not an exclusion criterion
  • Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • Malignancy associated with a paraneoplastic neuropathy
  • A history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • A history of known severe primary or secondary immunodeficiency (e.g., common variable immunodeficiency)
  • Significant other uncontrolled medical illnesses that may interfere with drug delivery or interpretation of results

PRIOR CONCURRENT THERAPY:

  • No live vaccine therapy within 30 days of enrollment
  • No plasmapheresis within 3 months
  • No high-dose intravenous immunoglobulin, chemotherapeutic agents, or high-dose corticosteroids (> 10 mg daily or every other day) within 3 months
  • No systemic corticosteroids within 3 months (unless needed for adrenal insufficiency or at a stable dose ≤ 10 mg daily)
  • No high-dose (> 250 mg/day) vitamin B6 within the past month
  • No prior treatment with thalidomide or neurotoxic drugs (e.g., vinca alkaloids, taxol, or platinum)
Both
21 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00588822
1191-04, UL1RR024150
Yes
Alvaro Moreno Aspitia, Mayo Clinic - Jacksonville
Mayo Clinic
  • Genentech, Inc.
  • Biogen Idec
  • National Center for Research Resources (NCRR)
Principal Investigator: Benn E. Smith, MD Mayo Clinic
Mayo Clinic
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP